Nippon Kayaku announce results of Phase III clinical study of its in-house developed polymeric micelle anti-cancer drug NK105
Posted on July 12, 2016
Nippon Kayaku Co., Ltd. announced that in a phase III clinical study of its in-house developed polymeric micelle anti-cancer drug NK105 in patients with metastatic or recurrent breast cancer, the primary endpoint of the study, progression free survival (PFS), did not meet the prespecified statistical criteria.
The study is a randomized, multinational study comparing weekly administration of NK105 versus Paclitaxel in terms of efficacy and safety in patients with metastatic or recurrent breast cancer.
The primary endpoint of the study is statistical non-inferiority of PFS. Detailed efficacy and safety analyses from this study are expected to be presented at an upcoming scientific congress. Future plans for the development of NK105 will be further examined.
Press release from https://www.nipponkayaku.co.jp
Related Topics and Keywords
Nippon Kayaku, NK105, Phase III clinical study, polymeric micelle anti-cancer drug
Subscribe to our FREE newsletter and WEBINAR UPDATES
We will not sell or give your information to a third party. See our Privacy Policy